Home » Posts tagged with » artificial intelligence
Curi Bio acquires Dana Solutions to boost drug discovery platforms

Curi Bio acquires Dana Solutions to boost drug discovery platforms

Curi Bio, a developer of human iPSC-based platforms for drug discovery, has acquired Dana Solutions, a provider of artificial intelligence and machine learning technologies for in vitro cell-based assays. Financial terms of the deal were not disclosed by the parties. Curi Bio, through the acquisition, will get access to Dana Solutions’ artificial intelligence and machine […]

Apollo Hospitals to use AI platform from Zebra Med for COVID-19 detection

Zebra Medical Vision (Zebra-Med), an Israel-based deep-learning medical imaging analytics company, said that its software will be deployed by India’s Apollo Hospitals Group to help its doctors in efficient and accurate diagnoses of COVID-19, by leveraging the former’s0 AI1 platform. The duo entered into a collaboration in March 2019 for deploying Zebra Medical Vision’s artificial […]

Continue reading …
AI drug discovery company Exscientia raises $60m in Series C round

Exscientia, a UK-based artificial intelligence (AI) drug discovery company, has secured $60 million in a Series C financing round led by new investor Novo Holdings, a Danish firm, which is fully owned by the Novo Nordisk Foundation. Existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital also took part in the funding round […]

Continue reading …
Cyclica, Genome Institute of Singapore sign drug discovery partnership

Canadian biotech company Cyclica has signed a multi-year and multi-project drug discovery partnership with the Genome Institute of Singapore (GIS) in oncology and related diseases. The partners will undertake research efforts, which will span from polypharmacology profiling to novel compound design for diverse drug discovery programs. The collaboration will utilize the deep expertise of Genome […]

Continue reading …
behold.ai red dot algorithm identifies chest x-rays of coronavirus patients as abnormal

behold.ai claimed that its artificial intelligence-based red dot algorithm has been shown to have quickly identified chest X-rays from COVID-19 patients as ‘abnormal’. The UK-based healthtech company expects the ‘instant triage’ to enable an expedited diagnosis of novel coronavirus cases and ensure resources are properly allocated. According to behold.ai, its red dot algorithm was trained […]

Continue reading …
BioDuro launches AI-driven COVID-19 nanobody therapeutic program

BioDuro said that it has launched a COVID-19 nanobody therapeutic program by leveraging its biologics discovery platform, which makes use of artificial intelligence computing and high-speed DNA mutagenesis technology. The life sciences contract research and development organization expects to screen over 10 billion human synthetic antibodies generated by its technology platform. BioDuro said that its […]

Continue reading …
COVID-19 treatment : Cyclica, Institute of Materia Medica partner on drug repurposing for coronavirus

COVID-19 treatment : The Institute of Materia Medica, Chinese Academy of Medical Sciences has entered into a collaboration with Canadian biotech company Cyclica for discovering antiviral drug candidates for COVID-19 (novel coronavirus) and for exploring opportunities for designing multi-targeted antiviral compounds. According to the partners, new drug development efforts to tackle the prevailing pandemic of […]

Continue reading …
AstraZeneca taps into Gatehouse Bio’s sRNAlytics AI platform for drug discovery

US biodata company Gatehouse Bio is joining forces with pharma giant AstraZeneca to accelerate the discovery of new drugs for respiratory and cardiovascular diseases using sRNAlytics, the former’s artificial intelligence (AI)-driven platform. According to Gatehouse Bio, the sRNAlytics platform is capable of identifying new small RNA (sRNA) signatures and can illuminate molecular pathways correlated to […]

Continue reading …
Terason, DiA bring AI-based cardiac solutions for ultrasound devices

Terason, a US ultrasound imaging company, has partnered with DiA Imaging Analysis, an artificial intelligence-based solutions provider for ultrasound analysis, to provide cardiac solutions for the former’s point-of-care ultrasound devices. The partnership is expected to help clinicians in hospitals and outpatient settings with more accurate and objective image analysis, who otherwise commonly analyze ultrasound images […]

Continue reading …
Yuhan Pharmaceuticals to use Cyclica’s AI-driven drug discovery platform

Yuhan Pharmaceuticals has entered into a collaboration with Canadian biotechnology company Cyclica to use the latter’s artificial intelligence (AI) driven integrated drug discovery platform in two separate research and development (R&D) programs in oncology. The South Korean healthcare company said that it is looking to adopt innovative technologies to boost its drug development efforts. In […]

Continue reading …
Page 1 of 212